ABSTRACT
BACKGROUND: The Janus kinase (JAK) pathway mediates the activity of many asthma-relevant cytokines, including IL-4 and IL-13. GDC-0214 is a potent, inhaled, small-molecule JAK inhibitor being developed for the treatment of asthma. OBJECTIVE: We sought to determine whether GDC-0214 reduces fractional exhaled nitric oxide (Feno), a JAK1-dependent biomarker of airway inflammation, in patients with mild asthma. METHODS: We conducted a double-blind, randomized, placebo-controlled, phase 1 proof-of-activity study in adults with mild asthma and Feno higher than 40 parts per billion (ppb). Subjects were randomized 2:1 (GDC-0214:placebo) into 4 sequential ascending-dose cohorts (1 mg once daily [QD], 4 mg QD, 15 mg QD, or 15 mg twice daily). All subjects received 4 days of blinded placebo, then 10 days of either active drug or placebo. The primary outcome was placebo-corrected percent reduction in Feno from baseline to day 14. Baseline was defined as the average Feno during the blinded placebo period. Pharmacokinetics, safety, and tolerability were also assessed. RESULTS: Thirty-six subjects (mean age, 28 years; 54% females) were enrolled. Mean Feno at baseline across all subjects was 93 ± 43 ppb. At day 14, placebo-corrected difference in Feno was -23% (95% CI, -37.3 to -9) for 15 mg QD and -42% (95% CI, -57 to -27.4) for 15 mg twice daily. Higher plasma exposure was associated with greater Feno reduction. No dose-limiting adverse events, serious adverse events, or treatment discontinuations occurred. There were no major imbalances in adverse events or laboratory findings, or evidence of systemic JAK inhibition. CONCLUSIONS: GDC-0214, an inhaled JAK inhibitor, caused dose-dependent reductions in Feno in mild asthma and was well tolerated without evidence of systemic toxicity.
Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Janus Kinase Inhibitors/therapeutic use , Nitric Oxide/metabolism , Adolescent , Adult , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/pharmacokinetics , Anti-Asthmatic Agents/pharmacology , Asthma/metabolism , Double-Blind Method , Exhalation , Female , Humans , Janus Kinase Inhibitors/blood , Janus Kinase Inhibitors/pharmacokinetics , Janus Kinase Inhibitors/pharmacology , Male , Young AdultABSTRACT
SRS27, an andrographolide analogue, had been proven to have therapeutic properties at a dose of 3 mg/kg in both in vitro and in vivo asthma models of our previous study. The present study focuses on the pharmacokinetic and toxicity profile of this compound to provide further evidence for the development of this compound as an anti-asthma agent. A simple pharmacokinetic study was performed in female BALB/c mice to measure blood plasma concentration of the compound at therapeutic dose. At a single dose of 3 mg/kg, SRS27 had a relatively short half-life but was able to achieve a concentration range of 13-19 µM that is related to its in vitro bioactivities. With regard to toxicity profile, SRS27 appears to be safe, as no histopathological changes were observed in the liver, kidneys and ovaries of SRS27-treated female BALB/c mice. In addition, there was no significant change in the mean body weight and organ weight of the animals in the SRS27-treated groups compared with the vehicle-treated control group at the end of the treatment. This fully supports the absence of any significant changes in peripheral blood leukocyte counts of SRS27-treated mice. Rewardingly, this acute toxicity study also revealed that SRS27 has a wide therapeutic window as no toxicity symptoms were detected with a dose up to 60 mg/kg daily when tested for 14 days. These results provide strong justification for further investigation of SRS27 as a potential new anti-asthma agent.
Subject(s)
Anti-Asthmatic Agents/pharmacokinetics , Anti-Asthmatic Agents/toxicity , Diterpenes/pharmacokinetics , Diterpenes/toxicity , Lactones/pharmacokinetics , Lactones/toxicity , Animals , Anti-Asthmatic Agents/blood , Biological Availability , Diterpenes/blood , Female , Kidney/anatomy & histology , Kidney/drug effects , Lactones/blood , Liver/anatomy & histology , Liver/drug effects , Lung/anatomy & histology , Lung/drug effects , Mice, Inbred BALB C , Ovary/anatomy & histology , Ovary/drug effectsABSTRACT
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate. PubMed and Web of Science were searched for phase II and phase III randomized clinical trials with monoclonal antibodies targeting key mediators of type 2-associated asthma. Thirty trials were selected involving biologics that target the IL-5 pathway, IL-13, the common IL-4 and IL-13 receptor, IL-9, IL-2 and TSLP. As no head-to-head trials were retrieved from literature, we performed an arm-based network meta-analysis to compare effects on exacerbation rate between the different treatments.Mepolizumab, reslizumab and benralizumab significantly reduced the risk of exacerbations compared to placebo (by 47-52%, 50-60%, and 28-51% respectively). Reslizumab and benralizumab also improved lung function. Dupilumab and tezepelumab improved lung function in frequent exacerbators. Lebrikizumab had no significant effect on the number of exacerbations, symptom control or health-related quality of life. Tralokinumab improved lung function compared to placebo. Network meta-analysis of all treatment and placebo arms, showed no superiority of one biologic over the others. Large reductions in exacerbation rates were observed compared to placebo, though only benralizumab was sufficiently powered (n = 2051) to demonstrate significantly decreased exacerbation rates in the subgroup analysis of IL-5 acting agents compared to placebo.Monoclonal antibodies such as mepolizumab, reslizumab and benralizumab have proven their benefit to reduce exacerbation rates in severe persistent eosinophilic asthma in the published trials. However, no statistically significant superiority was observed of one biologic over the other in the network meta-analysis. More studies with direct head to head comparisons and better defined endotypes are required.
Subject(s)
Anti-Asthmatic Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Asthma/drug therapy , Anti-Asthmatic Agents/blood , Antibodies, Monoclonal/blood , Asthma/blood , Asthma/diagnosis , Humans , Network Meta-Analysis , Randomized Controlled Trials as Topic/methodsABSTRACT
BACKGROUND: Asthma is a heterogeneous and complex disease in both its clinical course and response to treatment. IL-13 is central to Type 2 inflammation and contributes to many features of asthma. In a previous Phase 2 study, lebrikizumab, an anti-IL-13 monoclonal antibody, did not significantly improve FEV1 in mild-to-moderate asthma patients not receiving ICS therapy. This Phase 3 study was designed to further assess the efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma treated with daily short-acting ß2-agonist therapy alone. METHODS: Adult patients with mild-to-moderate asthma were randomised to receive lebrikizumab 125â¯mg subcutaneously (SC), placebo SC, or montelukast 10â¯mg orally for 12 weeks, with an 8-week follow-up period. The primary efficacy endpoint was absolute change in pre-bronchodilator FEV1 from baseline at Week 12. FINDINGS: A total of 310 patients were randomised and dosed in the study. The mean absolute change in FEV1 from baseline at Week 12 was higher in the lebrikizumab-treated arm compared with placebo (150â¯mL versus 67â¯mL); however, this improvement did not achieve statistical significance (overall adjusted difference of 83â¯mL [95% CI: -3, 170]; pâ¯=â¯.06). Montelukast did not improve FEV1 as compared with placebo. Lebrikizumab was generally safe and well tolerated during the study. INTERPRETATION: Lebrikizumab did not significantly improve FEV1 in mild-to-moderate asthma patients at a dose expected to inhibit the IL-13 pathway. Inhibiting IL-13 in this patient population was not sufficient to improve lung function. These data support the findings of a previous trial of lebrikizumab in patients not receiving ICS. CLINICAL TRIALS REGISTRY NUMBER: This trial was registered under NCT02104674 at http://www.clinicaltrials.gov.
Subject(s)
Anti-Asthmatic Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Asthma/drug therapy , Acetates/therapeutic use , Administration, Inhalation , Adult , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/adverse effects , Anti-Asthmatic Agents/blood , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/blood , Asthma/physiopathology , Cyclopropanes , Double-Blind Method , Female , Forced Expiratory Volume/drug effects , Glucocorticoids/administration & dosage , Humans , Injections, Subcutaneous , Male , Middle Aged , Quinolines/therapeutic use , Severity of Illness Index , Sulfides , Treatment Failure , Treatment OutcomeABSTRACT
We have developed a selective indole antagonist (230) targeting the OXE receptor for the potent eosinophil chemoattractant 5-oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid), that may be useful for the treatment of eosinophilic diseases such as asthma. In previous studies we identified ω2-oxidation of the hexyl side chain of racemic 230 as a major metabolic route in monkeys, but also obtained evidence for another pathway that appeared to involve hydroxylation of the hexyl side chain close to the indole. The present study was designed to investigate the metabolism of the active S-enantiomer of 230 (S230) and to identify the novel hydroxy metabolite and its chirality. Following oral administration, S230 rapidly appeared in the blood along with metabolites formed by a novel and highly stereospecific α-hydroxylation pathway, resulting in the formation of αS-hydroxy-S230. The chirality of α-hydroxy-S230 was determined by the total synthesis of the relevant diastereomers. Of the four possible diastereomers of α-hydroxy-230 only αS-hydroxy-S230 has significant OXE receptor antagonist activity and only this diastereomer was found in significant amounts in blood following oral administration of S230. Other novel metabolites of S230 identified in plasma by LC-MS/MS were αS,ω2-dihydroxy-S230 and glucuronides of S230 and ω2-hydroxy-S230. Thus the alkyl side chain of S230, which is essential for its antagonist activity, is also the major target of the metabolic enzymes that terminate its antagonist activity. Modification of this side chain might result in the development of related antagonists with improved metabolic stability and efficacy.
Subject(s)
Anti-Asthmatic Agents/pharmacokinetics , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Arachidonic Acids/antagonists & inhibitors , Chemotactic Factors/antagonists & inhibitors , Indoles/pharmacokinetics , Keto Acids/pharmacokinetics , Receptors, Eicosanoid/antagonists & inhibitors , Administration, Oral , Alkylation , Animals , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/blood , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Arachidonic Acids/metabolism , Chemotactic Factors/metabolism , Eosinophils/drug effects , Eosinophils/immunology , Eosinophils/metabolism , Female , Glucuronides/blood , Glucuronides/chemistry , Glucuronides/pharmacology , Humans , Hydroxylation , Inactivation, Metabolic , Indoles/administration & dosage , Indoles/blood , Indoles/chemistry , Indoles/pharmacology , Keto Acids/administration & dosage , Keto Acids/blood , Keto Acids/chemistry , Keto Acids/pharmacology , Macaca fascicularis , Molecular Structure , Neutrophils/drug effects , Neutrophils/immunology , Neutrophils/metabolism , Receptors, Eicosanoid/agonists , Receptors, Eicosanoid/metabolism , StereoisomerismABSTRACT
AZD5423 is a novel, inhaled, selective glucocorticoid receptor modulator (SGRM), which in an allergen challenge model in asthma patients improved lung function and airway hyper-reactivity. In the current trial, AZD5423 was for the first time tested in patients with chronic obstructive pulmonary disease (COPD). In this double-blind, randomized and parallel group study, we examined airway and systemic effects of two doses of AZD5423, inhaled via Turbuhaler for 12 weeks, in 353 symptomatic patients with COPD (average pre-bronchodilator forced expiratory volume in one-second (FEV1) at screening was 50-52% of predicted normal). Pre-bronchodilator FEV1 was primary variable, with other lung function parameters plus symptoms and 24-hr plasma cortisol being secondary variables. Plasma concentrations of AZD5423 were also measured. Effects were compared against placebo and a reference glucocorticoid receptor agonist control. Neither AZD5423, at doses which have shown to be efficacious in allergen-induced asthma, nor the reference control, at double the approved dose, had any clinically meaningful effect in the patient population studied in regard to lung function or markers of inflammation. Both GR modulators were well tolerated and did suppress 24-hr cortisol. This study suggests that the selected population of patients with COPD does not respond to treatment with AZD5423 as regards lung function, while showing the expected systemic effects. It cannot be ruled out that a favourable lung function response of AZD5423 can be evoked using another experimental setting and/or within a different population of patients with COPD.
Subject(s)
Acetamides/administration & dosage , Anti-Asthmatic Agents/administration & dosage , Indazoles/administration & dosage , Lung/drug effects , Pulmonary Disease, Chronic Obstructive/drug therapy , Receptors, Glucocorticoid/drug effects , Acetamides/adverse effects , Acetamides/blood , Administration, Inhalation , Aged , Anti-Asthmatic Agents/adverse effects , Anti-Asthmatic Agents/blood , Double-Blind Method , Female , Forced Expiratory Volume , Humans , Indazoles/adverse effects , Indazoles/blood , Lung/metabolism , Lung/physiopathology , Male , Middle Aged , Nebulizers and Vaporizers , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/metabolism , Pulmonary Disease, Chronic Obstructive/physiopathology , Receptors, Glucocorticoid/metabolism , Time Factors , Treatment Outcome , Vital CapacitySubject(s)
Adrenal Cortex Hormones/blood , Anti-Asthmatic Agents/blood , Asthma/drug therapy , Beclomethasone/blood , Medication Adherence , Administration, Inhalation , Adrenal Cortex Hormones/administration & dosage , Adult , Anti-Asthmatic Agents/administration & dosage , Beclomethasone/administration & dosage , Female , Humans , Male , Middle Aged , Pilot Projects , Treatment Adherence and Compliance , Young AdultABSTRACT
The chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells (CRTh2) is a G protein-coupled receptor expressed on the leukocytes most closely associated with asthma and allergy like eosinophils, mast cells, Th2-lymphocytes and basophils. At present it is clear that CRTh2 mediates most prostaglandin D2 (PGD2) pro-inflammatory effects and as a result antagonists for this receptor have reached asthma clinical studies showing a trend of lung function improvement. The challenge remains to identify compounds with improved clinical efficacy when administered once a day. Herein we described the pharmacological profile of LAS191859, a novel, potent and selective CRTh2 antagonist. In vitro evidence in GTPγS binding studies indicate that LAS191859 is a CRTh2 antagonist with activity in the low nanomolar range. This potency is also maintained in cellular assays performed with human eosinophils and whole blood. The main differentiation of LAS191859 vs other CRTh2 antagonists is in its receptor binding kinetics. LAS191859 has a residence time half-life of 21h at CRTh2 that translates into a long-lasting in vivo efficacy that is independent of plasma levels. We believe that the strategy behind this compound will allow optimal efficacy and posology for chronic asthma treatment.
Subject(s)
Anti-Asthmatic Agents/pharmacology , Eosinophils/drug effects , Prostaglandin Antagonists/pharmacology , Pyridines/pharmacology , Pyrroles/pharmacology , Receptors, Immunologic/antagonists & inhibitors , Receptors, Prostaglandin/antagonists & inhibitors , Animals , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/chemistry , Anti-Asthmatic Agents/pharmacokinetics , CHO Cells , Cell Shape/drug effects , Chemotaxis, Leukocyte/drug effects , Cricetulus , Dogs , Dose-Response Relationship, Drug , Drug Design , Eosinophils/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Guinea Pigs , Half-Life , Kinetics , Male , Mice , Prostaglandin Antagonists/blood , Prostaglandin Antagonists/chemistry , Prostaglandin Antagonists/pharmacokinetics , Protein Binding , Pyridines/blood , Pyridines/chemistry , Pyridines/pharmacokinetics , Pyrroles/blood , Pyrroles/chemistry , Pyrroles/pharmacokinetics , Rats, Wistar , Receptors, Immunologic/blood , Receptors, Immunologic/genetics , Receptors, Prostaglandin/blood , Receptors, Prostaglandin/genetics , TransfectionABSTRACT
YJC-10592, a novel chemokine receptor 2 (CCR-2) antagonist, was developed for treating asthma and atopic dermatitis. We studied the pharmacokinetic characteristics of YJC-10592 after intravenous (5, 10 and 20 mg/kg) and oral (100 and 200 mg/kg) administration of the drug to rats. Tissue distribution of YJC-10592 was also evaluated after intravenous administration of YJC-10592, 10 mg/kg, to rats. The pharmacokinetics of YJC-10592 was dose-dependent from 20 mg/kg after intravenous administration to rats. The values of the area under the plasma concentration-time curve from time zero to infinity (AUC) of YJC-10592 were dose-dependent from 20 mg/kg and the time-averaged total body (CL) and nonrenal (CLNR) clearances of YJC-10592 were significantly lower at dose of 20 mg/kg, suggesting that saturable metabolism may be involved. The absolute bioavailability (F) of YJC-10592 was generally low (<2.55 %) for both oral doses due to incomplete absorption and low urinary excretion. YJC-10592 had a great affinity to all rat tissues studied except brain, which was supported by a relatively high value of the apparent volume of distribution at steady state (V ss) (890-1385 mL/kg). In conclusion, YJC-10592 showed dose-dependent pharmacokinetics and low F value due to slower elimination and incomplete absorption.
Subject(s)
Acetamides/pharmacokinetics , Anti-Asthmatic Agents/pharmacokinetics , Benzamides/pharmacokinetics , Drug Discovery , Receptors, CCR2/antagonists & inhibitors , Acetamides/administration & dosage , Acetamides/blood , Acetamides/pharmacology , Administration, Oral , Animals , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/pharmacology , Benzamides/administration & dosage , Benzamides/blood , Benzamides/pharmacology , Blood Proteins/metabolism , Drug Stability , Injections, Intravenous , Male , Molecular Structure , Organ Specificity , Protein Binding , Rats , Rats, Sprague-Dawley , Tissue DistributionABSTRACT
AZD5423 is a selective glucocorticosteroid receptor modulator developed for the inhaled use in asthma and COPD. This study reports the initial, first-in-man, single and repeat dose-escalating studies in healthy male individuals, including one cohort of male Japanese individuals. Inhaled, nebulized AZD5423 was safe and well tolerated up to and including the highest doses tested for up to 2 weeks of once-daily treatment. Plasma exposure suggested dose-proportional pharmacokinetics and dose-related effects on 24-hr plasma and urine cortisol. There were no or marginal effects on other biomarkers tested (osteocalcin, TRAP5b, DHEA-S and 4ß-OH-cholesterol). No clinically relevant differences in safety or pharmacokinetics could be distinguished between the two study populations, although hypothalamus-pituitary-adrenal (HPA) effects appeared to be marginally greater in the Japanese- versus the Caucasian-dominant study population. AZD5423, inhaled via nebulization, can be used in healthy individuals at doses of at least 300 µg for 2 weeks. The effects on the HPA axis reported herein, together with efficacy data reported elsewhere, indicate that benefit-risk ratio may be improved relative to conventional inhaled steroids.
Subject(s)
Acetamides/adverse effects , Anti-Asthmatic Agents/adverse effects , Drugs, Investigational/adverse effects , Indazoles/adverse effects , Receptors, Glucocorticoid/agonists , Acetamides/administration & dosage , Acetamides/blood , Acetamides/pharmacokinetics , Administration, Inhalation , Adult , Aerosols , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/pharmacokinetics , Asian People , Biomarkers/blood , Biomarkers/urine , Cohort Studies , Dose-Response Relationship, Drug , Double-Blind Method , Drugs, Investigational/administration & dosage , Drugs, Investigational/analysis , Drugs, Investigational/pharmacokinetics , Half-Life , Humans , Hydrocortisone/blood , Hydrocortisone/urine , Hypothalamo-Hypophyseal System/drug effects , Hypothalamo-Hypophyseal System/physiology , Indazoles/administration & dosage , Indazoles/blood , Indazoles/pharmacokinetics , Japan/ethnology , Male , Metabolic Clearance Rate , Pituitary-Adrenal System/drug effects , Pituitary-Adrenal System/physiology , Receptors, Glucocorticoid/metabolism , White People , Young AdultABSTRACT
BACKGROUND: A novel inhalation-driven multidose dry powder inhaler (MDPI) that eliminates the need for the patient to coordinate device actuation with inhalation has been developed for delivery of inhaled asthma medications. OBJECTIVE: To characterize the pharmacokinetics of single-dose fluticasone propionate (Fp) MDPI compared with single doses of Fp dry powder inhaler (DPI) and a metered-dose inhaler (MDI) in healthy subjects. METHODS: This was a single-center, open-label, randomized, three-period crossover, single-dose pilot study in healthy adults ages 18 to 45 years. Eligible subjects (N = 18) were randomized to one of six treatment sequences that contained three treatment arms: Fp MDPI 400 µg/inhalation × two inhalations (800 µg total dose); Fp DPI 250 µg/inhalation × four (1000 µg total dose); and Fp MDI 220 µg/inhalation × four (880 µg total dose). Pharmacokinetics (area under concentration-versus-time curve [AUC], maximum plasma concentration [Cmax], time to Cmax [tmax], and elimination half-life [t½]), safety, and tolerability were assessed for each treatment. RESULTS: Plasma Fp concentration-versus-time curves were comparable across treatments. Geometric mean AUC0-t and Cmax for Fp MDPI 800 µg were 19% and 18% higher, respectively, compared with Fp DPI 1000 µg, and 47% and 82% higher, respectively, compared with Fp MDI 880 µg. Median tmax (60.0-60.6 minutes) and median t1/2 (9.1-9.8 hours) were comparable across the three treatments. Single-dose Fp was well tolerated, with no new safety issues noted. CONCLUSION: Single-dose administration of Fp MDPI 800 µg produced systemic exposure comparable with those for Fp DPI 1000 µg and Fp MDI 880 µg.
Subject(s)
Anti-Asthmatic Agents/administration & dosage , Asthma/drug therapy , Dry Powder Inhalers , Fluticasone/administration & dosage , Metered Dose Inhalers , Administration, Inhalation , Adolescent , Adult , Anti-Asthmatic Agents/adverse effects , Anti-Asthmatic Agents/blood , Female , Fluticasone/adverse effects , Fluticasone/blood , Humans , Male , Middle Aged , Pharmacokinetics , Pilot Projects , Young AdultABSTRACT
OBJECTIVES: This study aimed to evaluate influence of ethnic factors on the pharmacokinetics of orally inhaled QMF149, a novel combination of an approved longacting ß2-agonist, indacaterol (Onbrez® Breezhaler® for COPD), and an approved inhaled corticosteroid, mometasone furoate (MF), (Asmanex® Twisthaler® for asthma), following multiple dose administration of QMF149 (indacaterol acetate/MF) 150/80 µg and 150/320 µg via the Breezhaler® device in healthy Japanese and Caucasian subjects. METHODS: This was a single-center, openlabel, multiple-dose, two-period, complete crossover study that randomized healthy Japanese and, age and weight matched Caucasian subjects to QMF149 150/80 µg or 150/320 µg once daily (o.d.) for 14 days in each period. Pharmacokinetics (PK) were assessed up to 24 hours on days 1 and 14. RESULTS: 24 Japanese and 24 Caucasian healthy subjects were enrolled. Indacaterol and MF had similar PK profiles across both the doses and both ethnic groups. The maximum geometric mean ratios (90% confidence interval (CI)) for Japanese vs. Caucasian subjects for Cmax were 1.23 (1.11 - 1.38) and 1.24 (1.11 - 1.38) for indacaterol and MF, respectively. For AUC, the maximum ratios were 1.22 (1.09 - 1.36) and 1.30 (1.18 - 1.44) for indacaterol and MF, respectively. The mild trend towards higher exposure in Japanese subjects could be explained by the fact that the mean body weight was 14% higher for Caucasians compared to their Japanese counterparts. No serious adverse events or discontinuations related to study medication were reported. CONCLUSION: The study demonstrated increase of mean exposure parameters in Japanese subjects vs. Caucasian subjects, which ranged between 19 - 23% and 17 - 30%, for indacaterol and MF components, respectively. Multiple doses of both the QMF149 dose levels were safe and well-tolerated in all subjects. Body weight was considered a key contributory factor for the observed difference in exposure. These results suggest no dose adjustment for QMF149 is required in Asian populations.
Subject(s)
Anti-Asthmatic Agents/pharmacokinetics , Asian People , Indans/pharmacokinetics , Pregnadienediols/pharmacokinetics , Quinolones/pharmacokinetics , White People , Administration, Inhalation , Adult , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/adverse effects , Anti-Asthmatic Agents/blood , Area Under Curve , Cross-Over Studies , Drug Combinations , Drug Monitoring , Humans , Indans/administration & dosage , Indans/adverse effects , Indans/blood , Japan , Male , Nebulizers and Vaporizers , Pregnadienediols/administration & dosage , Pregnadienediols/adverse effects , Pregnadienediols/blood , Quinolones/administration & dosage , Quinolones/adverse effects , Quinolones/blood , Young AdultABSTRACT
Development of high-concentration antibody formulations for subcutaneous administration remains challenging. Recently, a precipitation-redissolution method was proposed to prepare suspensions or precipitates of salt-dissociable protein-poly(amino acid) complexes. To elucidate the utility of this method for protein therapy, we investigated the feasibility of a precipitation-redissolution method using poly(amino acid) for high-concentration antibody formulation. Omalizumab and adalimumab formulations of 150 mg/mL could be prepared using poly-l-glutamic acid (polyE) from low-concentration stock solutions. Enzyme-linked immunosorbent assay, circular dichroism, and size-exclusion chromatography revealed that the formation of antibody-polyE complex and precipitation-redissolution process did not significantly affect the immunoreactivity or secondary structure of the antibodies. The precipitation-redissolution method was less time-consuming and more effective than lyophilization-redissolution, evaporation-redissolution, and ultrafiltration from the viewpoint of final yield. Scalability was confirmed from 400 µL to 1.0 L. The general toxicity and pharmacokinetic profiles of the antibody-polyE complex formulations were similar to those of conventional antibody formulations. These results suggested that the precipitation-redissolution method using poly(amino acid) has great potential as a concentration method for antibody formulation and medicinal use.
Subject(s)
Adalimumab/chemistry , Anti-Asthmatic Agents/chemistry , Anti-Inflammatory Agents/chemistry , Omalizumab/chemistry , Polyglutamic Acid/chemistry , Adalimumab/blood , Adalimumab/pharmacology , Animals , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/pharmacology , Anti-Inflammatory Agents/blood , Anti-Inflammatory Agents/pharmacology , Chemical Precipitation , Humans , Omalizumab/blood , Omalizumab/pharmacology , Polyglutamic Acid/blood , Polyglutamic Acid/pharmacology , Protein Structure, Secondary , RatsABSTRACT
The commercially available alpha-asarone injections (CA-ARE) were frequently found to cause severe anaphylactic reactions by the solubilizer contained in the formulation such as polysorbate 80 and propylene glycol. This study aimed to develop a new ARE injection using Kolliphor HS 15 as solubilizing agent (HS 15-ARE) by the dissolution method to resolve its poor solubility problem and reduce the anaphylaxis of CA-AREs caused by Polysorbate 80. The HS 15-ARE micelle showed a homogeneous round shape with the mean particle size of around 13.73 ± 0.02 nm, polydisperse index (PDI) of 0.19 ± 0.01 and solubilizing efficiency of 95.7% ± 2.4%. In vitro and in vivo studies showed that HS 15-ARE is a stable injection presenting the same pharmacokinetic profile with CA-ARE. Moreover, improved therapeutic effect was observed for HS 15-ARE in treating asthma compared to CA-ARE (p < 0.05) with no anaphylactic reactions observed. These results demonstrate that the new formulation of ARE (HS 15-ARE) has a great potential for replacing CA-AREs injections.
Subject(s)
Anaphylaxis/chemically induced , Anisoles/administration & dosage , Anti-Asthmatic Agents/administration & dosage , Asthma/drug therapy , Polyethylene Glycols/chemistry , Solvents/chemistry , Stearates/chemistry , Allylbenzene Derivatives , Anaphylaxis/blood , Animals , Anisoles/adverse effects , Anisoles/blood , Anisoles/therapeutic use , Anti-Asthmatic Agents/adverse effects , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/therapeutic use , Asthma/blood , Biological Availability , Cells, Cultured , Chemistry, Pharmaceutical , Disease Models, Animal , Drug Stability , Erythrocytes/drug effects , Guinea Pigs , Hemolysis/drug effects , Histamine/blood , Injections, Intravenous , Male , Molecular Structure , Particle Size , Rats, Wistar , Sheep , Surface Properties , Tissue DistributionABSTRACT
The dosing level and frequency of omalizumab are guided by a dosing table based on total serum immunoglobulin E (IgE) and bodyweight. Using a validated, mathematical simulation model (based on concentration data from 8 studies), we evaluated the impact of a revised omalizumab dosing table (every 4 weeks dosing regimen) on the pharmacokinetic and pharmacodynamic profiles of free and total IgE. Safety analysis, in patients with high levels of exposure to omalizumab, was done using data from the clinical and post-marketing databases. The model accurately predicted observed omalizumab, free and total IgE concentrations. After reaching steady-state, the average increase in exposure was 10%, even for patients with the highest concentrations at the upper 97.5th percentile. Free IgE suppression slightly increased in the initial phase, and slightly reduced at the trough of the dosing cycle, but average suppression remained similar for both regimens. The safety profile of omalizumab was similar for patients receiving higher or lower doses. Thus, doubling the dose of omalizumab, in a subset of patients receiving 225-300 mg of omalizumab (every 2 weeks dosing regimen) can efficiently suppress free IgE without compromising safety or efficacy.
Subject(s)
Anti-Asthmatic Agents/administration & dosage , Antibodies, Anti-Idiotypic/administration & dosage , Antibodies, Monoclonal, Humanized/administration & dosage , Models, Biological , Adolescent , Adult , Aged , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/pharmacokinetics , Anti-Asthmatic Agents/pharmacology , Antibodies, Anti-Idiotypic/blood , Antibodies, Anti-Idiotypic/pharmacology , Antibodies, Monoclonal, Humanized/blood , Antibodies, Monoclonal, Humanized/pharmacokinetics , Antibodies, Monoclonal, Humanized/pharmacology , Asthma/blood , Asthma/drug therapy , Body Weight , Child , Double-Blind Method , Drug Administration Schedule , Humans , Immunoglobulin E/blood , Middle Aged , Omalizumab , Young AdultABSTRACT
Pranlukast hydrate was demonstrated in a human site-of-absorption study to have extremely poor absorption properties in the lower gastrointestinal tract. The ratios of AUC0-24 in the distal small bowel and colon compared to stomach delivery were approximately 1/7 and 1/70, respectively. As a consequence, a gastroretentive double-layered tablet formulation (gastric swelling system; GSS), consisting of a swelling layer and a drug release layer, was developed for once-daily dosing. To study the gastric retention of the optimized GSS, an in vivo gamma scintigraphic study was carried out in nine healthy volunteers. The transit profiles demonstrated that the GSS was retained in the stomach for more than 10h. The plasma profile was prolonged, especially following administration after an evening meal. The human data validated the design concept and suggest that GSS could be a promising approach for the development of sustained-release formulation for drugs with a limited absorption window in the upper small bowel.
Subject(s)
Anti-Asthmatic Agents/pharmacokinetics , Chromones/pharmacokinetics , Drug Delivery Systems , Gastric Mucosa/metabolism , Adolescent , Adult , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/chemistry , Chromones/blood , Chromones/chemistry , Cross-Over Studies , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Gastrointestinal Transit , Humans , Male , Middle Aged , Young AdultABSTRACT
Montelukast, a leukotriene receptor antagonist, is a substrate of organic anion transporting OATP2B1 encoded by the SLCO2B1. We evaluated the effects of six non-synonymous (c.1175C>T, c.1457C>T, c.43C>T, c.935G>A, c.601G>A, and c.644A>T) polymorphisms and one promoter (g.-282G>A) polymorphism on the pharmacokinetics of montelukast. A single dose of 10 mg montelukast was administered in 24 healthy subjects. Its levels were measured up to 24 hours and a pharmacokinetic analysis was performed based on the SLCO2B1 polymorphisms. We did not encounter subjects with c.1175C>T, c.43C>T, or c.644A>T polymorphisms. The remaining SLCO2B1 polymorphisms did not affect plasma levels of montelukast, and pharmacokinetic parameters of montelukast did not differ among genotype groups. Oral clearance results were as follows: (1) 3.3 L/h for c.935GG, 3.0 L/h for c.935GA, and 3.5 L/h for c.935AA; (2) 3.4 L/h for c.1457CC, 2.9 L/h for c.1457CT, and 3.2 L/h for c.1457TT; (3) 3.2 L/h for c.601GG, 3.4 L/h for c.601GA, and 3.4 L/h for c.601AA; (4) 3.2 L/h for g.-282GG, 3.4 L/h for g.-282GA, and 3.2 L/h for g.-282AA. The findings suggest that SLCO2B1 polymorphisms do not affect the pharmacokinetics of montelukast and that SLCO2B1 polymorphisms appear to be a minor determinant of inter-individual variability of montelukast.
Subject(s)
Acetates/pharmacokinetics , Anti-Asthmatic Agents/pharmacokinetics , Leukotriene Antagonists/pharmacokinetics , Organic Anion Transporters/genetics , Quinolines/pharmacokinetics , Acetates/blood , Adult , Anti-Asthmatic Agents/blood , Cyclopropanes , Humans , Leukotriene Antagonists/blood , Male , Polymorphism, Single Nucleotide , Quinolines/blood , Sulfides , Young AdultABSTRACT
The DNAzyme hgd40 was shown to effectively reduce expression of the transcription factor GATA-3 RNA which plays an important role in the regulation of Th2-mediated immune mechanisms such as in allergic bronchial asthma. However, uptake, biodistribution and pharmacokinetics of hgd40 have not been investigated yet. We examined local and systemic distribution of hgd40 in naive mice and mice suffering from experimental asthma. Furthermore, we evaluated the pharmacokinetics as a function of dose following single and repeated administration in rats and dogs. Using intranasal administration of fluorescently labeled hgd40 we demonstrated that the DNAzyme was evenly distributed in inflamed asthmatic mouse lungs within minutes after single dose application. Systemic distribution was investigated in mice using radioactive labeled hgd40. After intratracheal application, highest amounts of hgd40 were detected in the lungs. High amounts were also detected in the bladder indicating urinary excretion as a major elimination pathway. In serum, low systemic hgd40 levels were detected already at 5 min post application (p.a.), subsequently decreasing over time to non-detectable levels at 2h p.a. As revealed by Single Photon Emission Computed Tomography, trace amounts of hgd40 were detectable in lungs up to 7 days p.a. Also in the toxicologically relevant rats and dogs, hgd40 was detectable in blood only shortly after inhalative application. The plasma pharmacokinetic profile was dose and time dependent. Repeated administration did not lead to drug accumulation in plasma of dogs and rats. These pharmacokinetic of hgd40 provide guidance for clinical development, and support an infrequent and convenient dose administration regimen.
Subject(s)
Anti-Asthmatic Agents/pharmacokinetics , DNA, Catalytic/pharmacokinetics , GATA3 Transcription Factor/metabolism , Administration, Inhalation , Animals , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/blood , Asthma/drug therapy , Asthma/metabolism , DNA, Catalytic/administration & dosage , DNA, Catalytic/blood , Dogs , Female , Lung/drug effects , Lung/metabolism , Male , Mice , Mice, Inbred BALB C , Microscopy, Confocal , Rats , Rats, Wistar , Species Specificity , Tissue DistributionABSTRACT
BACKGROUND: Asthma is a disease with marked heterogeneity in its clinical course and response to treatment. IL-13 is central to type 2 inflammation, which contributes to many key features of asthma. Lebrikizumab is an anti-IL-13 mAb previously reported to significantly improve lung function in patients with inadequately controlled asthma despite inhaled corticosteroid therapy, especially in periostin-high patients. OBJECTIVE: This phase II study investigated the efficacy and safety of IL-13 blockade with different doses of lebrikizumab in asthmatic patients not receiving inhaled corticosteroids. METHODS: Patients were randomized to receive 125, 250, or 500 mg of lebrikizumab or placebo subcutaneously monthly for 12 weeks with an 8-week follow-up period. The primary efficacy end point was the relative change in prebronchodilator FEV1 from baseline to week 12. RESULTS: A total of 212 patients were randomized. The mean relative change in FEV1 was numerically higher in all lebrikizumab dose groups versus the placebo group, although the difference was neither statistically nor clinically significant. There were no meaningful differences in changes in FEV1 between the dose groups and the placebo group by the periostin subgroup. Lebrikizumab treatment was associated with a reduced risk of treatment failure at all doses versus placebo (P < .001), and results were similar by the periostin subgroup, with no apparent differences between doses of lebrikizumab. Lebrikizumab was generally well tolerated. CONCLUSION: Blocking IL-13, a single cytokine, in this population of asthmatic patients is insufficient to improve lung function. There is evidence that IL-13 blockade may improve disease control, as measured by prevention of protocol-defined treatment failure in these patients.
Subject(s)
Anti-Asthmatic Agents/administration & dosage , Antibodies, Monoclonal/administration & dosage , Asthma/drug therapy , Interleukin-13/antagonists & inhibitors , Adult , Anti-Asthmatic Agents/blood , Anti-Asthmatic Agents/pharmacokinetics , Antibodies, Monoclonal/blood , Antibodies, Monoclonal/pharmacokinetics , Asthma/immunology , Asthma/physiopathology , Chemokine CCL17/blood , Dose-Response Relationship, Drug , Double-Blind Method , Eosinophils/cytology , Eosinophils/immunology , Female , Forced Expiratory Volume , Humans , Immunoglobulin E/blood , Leukocyte Count , Male , Monocyte Chemoattractant Proteins/bloodABSTRACT
In vitro measures of aerosol particles size, such as the fine particle mass, play a pivotal role for approval of inhaled anti-asthmatic drugs. However, the validity as a measure of dose to the lungs in children lacks evidence. In this study we investigated for the first time the association between an in vivo estimate of lung dose of inhaled drug in children and the corresponding particle size segments assessed ex vivo. Lung dose of fluticasone propionate after inhalation from a dry powder inhaler (Diskus®) was studied in 23 children aged 4-7 and 12-15 years with mild asthma. Six-hour pharmacokinetics was assessed after single inhalation. The corresponding emitted mass of drug in segments of aerosol particle size was assessed ex vivo by replicating the inhalation flows recorded by transducers built into the Diskus® inhaler and re-playing them in a breathing simulator. There was no correlation between any inhaled particle size segment and lung dose assessed by pharmacokinetics and adjusted for age and body size. Measures of particles size segments were not related to lung dose in children. Until further evidence is provided it may be warranted to emphasize pharmacokinetic or pharmacodynamic assessments of drug delivery to the lung.